Guideline for Simultaneous Treatment of Acute Decompensated Heart Failure and Community‑Acquired Pneumonia

Diagnostic Evaluation

Measure BNP or NT‑proBNP in all patients presenting with acute dyspnea and suspected heart failure to differentiate cardiac from infectious causes of respiratory symptoms; elevated cardiac biomarkers favor pulmonary edema. 1
Obtain bedside echocardiography in patients with suspected cardiogenic shock or unclear decompensation to guide hemodynamic management. 1
Transfer patients with cardiogenic shock promptly to a tertiary center equipped with 24/7 cardiac catheterization and mechanical circulatory support. 1

Initiate intravenous loop diuretics (e.g., furosemide 20–40 mg IV for diuretic‑naïve patients or an equivalent dose to the oral regimen for chronic users) as first‑line therapy for acute decompensated heart failure. 1
Monitor symptoms, urine output, renal function, and electrolytes frequently during diuretic therapy; adjust dosing as intermittent boluses or continuous infusion based on clinical response. 1
Continue guideline‑directed disease‑modifying agents (ACE inhibitors, beta‑blockers, mineralocorticoid receptor antagonists) in chronic HFrEF unless the patient is hemodynamically unstable or has contraindications. 1
Reserve inotropic agents for patients who are symptomatic hypotensive or hypoperfused, given their significant safety concerns. 1

Administer a β‑lactam (e.g., ceftriaxone, cefotaxime, ampicillin‑sulbactam, or ceftaroline) combined with a macrolide (preferably azithromycin) as the preferred regimen. 2
Use a respiratory fluoroquinolone (levofloxacin or moxifloxacin) as monotherapy when β‑lactam plus macrolide is contraindicated; outcomes are comparable. 2
Give the first antibiotic dose in the emergency department before hospital admission, as delays are associated with increased mortality. 2

Employ combination therapy with a β‑lactam (ceftriaxone, cefotaxime, or ampicillin‑sulbactam) plus azithromycin; this regimen is strongly recommended for critically ill patients. 2
Alternatively, combine a β‑lactam with a respiratory fluoroquinolone (levofloxacin 750 mg or moxifloxacin) when macrolide use is unsuitable. 2
Macrolide‑containing regimens reduce mortality by approximately 18 % relative risk (≈3 % absolute reduction) in critically ill patients compared with non‑macrolide regimens. 2

Add antipseudomonal agents (piperacillin‑tazobactam, cefepime, imipenem, or meropenem) plus ciprofloxacin/levofloxacin or an aminoglycoside plus azithromycin when risk factors for Pseudomonas aeruginosa are present (e.g., structural lung disease, recent broad‑spectrum antibiotics, recent hospitalization with parenteral antibiotics ≤90 days). 2
Include vancomycin or linezolid when MRSA risk factors exist (prior MRSA infection/colonization, IV drug use, recent influenza, known nasal colonization). 2

Treat for a minimum of 5 days once the patient has been afebrile for 48–72 hours and exhibits no more than one sign of clinical instability (e.g., tachycardia, tachypnea, hypotension, hypoxia, inability to maintain oral intake, altered mental status). 2
Switch from IV to oral antibiotics once the patient is hemodynamically stable, clinically improving, able to ingest medication, and has a functional gastrointestinal tract—typically after 2–3 days of IV therapy. 2
Discharge immediately after the IV‑to‑oral switch if the patient remains clinically stable, without requiring additional observation. 2
Do not extend antibiotic therapy beyond 5 days in clinically stable patients to limit resistance and adverse events. 2

Reassess daily the need for continued antibiotics; if pulmonary infiltrates resolve rapidly with diuresis alone (within 24–48 hours), consider stopping antibiotics when true pneumonia is unlikely. 1

Avoid reflexively treating all CHF patients with radiographic infiltrates as pneumonia; lack of fever, leukocytosis, and purulent sputum should raise suspicion for pure pulmonary edema. 2
Do not add MRSA or Pseudomonas coverage without documented risk factors, as this leads to unnecessary broad‑spectrum exposure. 2
Avoid macrolide monotherapy in regions where pneumococcal macrolide resistance exceeds 25 %. 2
Do not delay ICU admission for patients meeting severe CAP criteria, as delays increase mortality. 2
Do not discontinue evidence‑based heart‑failure medications (beta‑blockers, ACE inhibitors) unless the patient is hemodynamically unstable, to prevent worsening outcomes. 1